LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Home・Aktien・Novo Nordisk A-S

Novo Nordisk A-S

Geschlossen

Branche Gesundheitswesen

131.05 0.18

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

130.55

Max

131.39

Schlüsselkennzahlen
By Trading Economics
Einkommen	-5.4B 20B
Verkäufe	2.7B 68B
KGV Branchendurchschnitt	49.94 103.001
EPS	4.49
Gewinnspanne	29.459
EBITDA	-1.2B 36B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+10.59 upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	711M 471B
Vorheriger Eröffnungskurs	130.87
Vorheriger Schlusskurs	131.05

Nachrichtenstimmung

By Acuity

86%

14%

331 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

N/A / 134.62 Unterstützung & Widerstand

Novo Nordisk A-S Chart

Ähnliche Nachrichten

7. Aug. 2024, 10:13 UTC

Ergebnisse

Novo Nordisk's Wegovy Sales Disappoint -- 2nd Update

7. Aug. 2024, 06:58 UTC

Ergebnisse

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge -- Update

7. Aug. 2024, 06:10 UTC

Ergebnisse

Wegovy Maker Novo Nordisk Lifts Sales Guidance as Weight-Loss Drug Demand Continues to Surge

3. Sept. 2024, 11:09 UTC

Top News

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27. Aug. 2024, 05:30 UTC

Top News

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14. Aug. 2024, 12:01 UTC

Market Talk

Ergebnisse

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9. Aug. 2024, 11:30 UTC

Top News

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9. Aug. 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8. Aug. 2024, 15:44 UTC

Top News

Ergebnisse

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8. Aug. 2024, 11:36 UTC

Market Talk

Ergebnisse

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8. Aug. 2024, 07:16 UTC

Market Talk

Ergebnisse

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

7. Aug. 2024, 20:30 UTC

Top News

Eli Lilly Reports Earnings Thursday Amid a Stock Slump. Here's What to Expect. -- Barrons.com

7. Aug. 2024, 16:39 UTC

Ergebnisse

Novo Nordisk's Wegovy Sales Disappoint -- Update

7. Aug. 2024, 15:30 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk's Wegovy Sales Disappoint -- WSJ

7. Aug. 2024, 14:22 UTC

Top News

Ergebnisse

It Isn't Time to Worry About Wegovy Yet -- Heard on the Street -- WSJ

7. Aug. 2024, 12:28 UTC

Market Talk

Ergebnisse

Novo Nordisk's Core Products Disappoint -- Market Talk

7. Aug. 2024, 12:04 UTC

Ergebnisse

Novo Nordisk Execs Were Speaking on a Call After 2Q Earnings

7. Aug. 2024, 11:34 UTC

Ergebnisse

Novo Nordisk US Head: As Wegovy Volumes Go Up, Prices Will Come Down

7. Aug. 2024, 11:34 UTC

Ergebnisse

Novo Nordisk CEO: When You Move Into New Sales Channels it Comes With a Discount

7. Aug. 2024, 11:34 UTC

Ergebnisse

Novo Nordisk CEO: Wegovy Now Covered in 20 States Through Medicaid

7. Aug. 2024, 11:05 UTC

Market Talk

Ergebnisse

Novo Nordisk Delivers Messy Quarter as Wegovy Misses The Mark -- Market Talk

7. Aug. 2024, 10:55 UTC

Ergebnisse

Stock Market Madness Highlights This Problem for -2-

7. Aug. 2024, 10:55 UTC

Ergebnisse

Stock Market Madness Highlights This Problem for Novo Nordisk and Super Micro. And 5 Other Things to Know Today. -- Barrons.com

7. Aug. 2024, 09:07 UTC

Ergebnisse

Heiße Aktien

Stocks to Watch Wednesday: Super Micro, Rivian, Airbnb -- WSJ

7. Aug. 2024, 08:55 UTC

Top News

These Stocks Are Moving the Most Today: Super Micro, Lumen, Airbnb, Rivian, Fortinet, Upstart, Disney, and More -- Barrons.com

7. Aug. 2024, 07:32 UTC

Market Talk

Ergebnisse

Novo Nordisk Wegovy Sales Disappoint -- Market Talk

7. Aug. 2024, 05:45 UTC

Ergebnisse

Novo Nordisk Declares Interim Dividend of DKK3.50

7. Aug. 2024, 05:44 UTC

Ergebnisse

Novo Nordisk 2Q Gross Margin 84.9% Vs 85.5%, Op Margin 38.1% Vs 44.0%

7. Aug. 2024, 05:40 UTC

Ergebnisse

Novo Nordisk 2Q Wegovy Drug Sales DKK11.66B Vs DKK7.52B

7. Aug. 2024, 05:38 UTC

Ergebnisse

Novo Nordisk: Sales Growth Has Resulted in Periodic Supply Constraints, Related Drug Shortage Notifications

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S Prognose

Kursziel

By TipRanks

10.59% Vorteil

12-Monats-Prognose

Durchschnitt 144.75 USD 10.59%

Hoch 166 USD

Tief 82.5 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Novo Nordisk A-S – Dist abgegeben haben.

Technischer Score

By Trading Central

N/A / 134.62Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bullish event.

Stimmung

By Acuity

331 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

Über Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.